COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

被引：0
|
作者：
Naoise C. Synnott
David O’Connell
John Crown
Michael J. Duffy
机构：
[1] University College Dublin,UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research
[2] University College Dublin,UCD School of Biomolecular & Biomedical Science
[3] St. Vincent’s University Hospital,Department of Medical Oncology
[4] St. Vincent’s University Hospital,UCD Clinical Research Centre
来源：
Breast Cancer Research and Treatment | 2020年 / 179卷
关键词：
p53; TP53; COTI-2; Triple-negative breast cancer; Treatment; APR-246;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 56
页数：9
相关论文
共 50 条
  • [41] Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
    Synnott, Naoise C.
    Bauer, Matthias R.
    Madden, Stephen
    Murray, Alyson
    Klinger, Rut
    O'Donovan, Norma
    O'Connor, Darran
    Gallagher, William M.
    Crown, John
    Fersht, Alan R.
    Duffy, Michael J.
    CANCER LETTERS, 2018, 414 : 99 - 106
  • [42] Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition
    Peng, Jingyu
    Yang, Ming
    Bi, Ran
    Wang, Yueyuan
    Wang, Chunxi
    Wei, Xue
    Zhang, Zhihao
    Xie, Xiao
    Wei, Wei
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [43] Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells
    Ming Lei
    Yun-Long Zhang
    Feng-Ying Huang
    Heng-Yu Chen
    Ming-Hui Chen
    Ri-Hong Wu
    Shu-Zhen Dai
    Gui-Sheng He
    Guang-Hong Tan
    Wu-Ping Zheng
    Scientific Reports, 13
  • [44] Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells
    Lei, Ming
    Zhang, Yun-Long
    Huang, Feng-Ying
    Chen, Heng-Yu
    Chen, Ming-Hui
    Wu, Ri-Hong
    Dai, Shu-Zhen
    He, Gui-Sheng
    Tan, Guang-Hong
    Zheng, Wu-Ping
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [45] Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells
    Tahaney, William M.
    Qian, Jing
    Powell, Reid
    Moyer, Cassandra L.
    Ma, Yanxia
    Nguyen, Nghi
    Hill, Jamal
    Stephan, Clifford
    Mazumdar, Abhijit
    Davies, Peter J. A.
    Brown, Powel H.
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer
    Zhang, Qian-Qian
    Chen, Jian
    Zhou, Da-Lei
    Duan, You-Fa
    Qi, Cui-Ling
    Li, Jiang-Chao
    He, Xiao-Dong
    Zhang, Min
    Yang, Yong-Xia
    Wang, Lijing
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2017, 13 (04): : 471 - 479
  • [47] Targeting mutant p53 with arsenic trioxide: A preclinical study focusing on triple negative breast cancer
    Rajaram, Subhasree
    Synnott, Naoise C.
    Crown, John
    Madden, Stephen F.
    Duffy, Michael J.
    TRANSLATIONAL ONCOLOGY, 2024, 46
  • [48] Triple Negative Breast Cancer: Increased Apoptotic Response to Platinum is Dependent on Mutant P53 Level
    Oduah, Eziafa I.
    Szomju, Barbara B.
    Akande, Oluwatoyin E.
    Grossman, Steven R.
    JOURNAL OF WOMENS HEALTH, 2019, 28 (06) : 13 - 14
  • [49] TARGETING MUTANT P53 FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER: A PRE-CLINICAL STUDY
    Lawless, A.
    O'Grady, S.
    Tang, M.
    Duffy, M. J.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (SUPPL 1) : S20 - S20
  • [50] Luteolin inhibits metastasis of triple-negative breast cancer cells to the lungs
    Cook, Matthew T.
    Liang, Yayun
    Besch-Williford, Cynthia
    Hyder, Salman
    CANCER RESEARCH, 2017, 77
12345